$65.74
1.62% yesterday
Nasdaq, Sep 20, 10:04 pm CET
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Incyte Stock price

$65.74
+1.36 2.11% 1M
+7.50 12.88% 6M
+2.95 4.70% YTD
+5.37 8.90% 1Y
-10.17 13.40% 3Y
-15.47 19.05% 5Y
+18.33 38.66% 10Y
Nasdaq, Closing price Fri, Sep 20 2024
-1.08 1.62%
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Key metrics

Market capitalization $12.87b
Enterprise Value $11.39b
P/E (TTM) P/E ratio 188.28
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.95
P/S ratio (TTM) P/S ratio 3.34
P/B ratio (TTM) P/B ratio 4.27
Revenue growth (TTM) Revenue growth 9.78%
Revenue (TTM) Revenue $3.86b
EBIT (operating result TTM) EBIT $33.74m
Free Cash Flow (TTM) Free Cash Flow $-138.12m
Cash position $1.52b
EPS (TTM) EPS $0.35
P/E forward 81.41
P/S forward 3.10
EV/Sales forward 2.75
Short interest 9.98%
Show more

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Incyte forecast:

12x Buy
48%
12x Hold
48%
1x Sell
4%

Analyst Opinions

25 Analysts have issued a Incyte forecast:

Buy
48%
Hold
48%
Sell
4%

Financial data from Incyte

Dec '23
+/-
%
Net Profit 598 598
75% 75%
16%
Depreciation and Amortization 83 83
22% 22%
2%
Stock Compensation 216 216
15% 15%
6%
Operating Cash Flow 496 496
49% 49%
13%
Investments 47 47
39% 39%
1%
Dividend Paid - -
-
-
Free Cash Flow 464 464
48% 48%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Neutral
PRNewsWire
2 days ago
– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg every 2 weeks dose achieving a complete or partial response within the first six months of treatment – – Niktimvo approved by U.S. FDA for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least ...
Neutral
Business Wire
6 days ago
DOHA, Qatar--(BUSINESS WIRE)--Doğuş Technology, one of Turkey's leading tech companies, will showcase its innovative, technology-driven solutions for the construction industry at ConteQ Expo 2024, alongside Doğuş Construction, at the Qatar National Convention Center from September 16-18. Both companies will present their projects that drive sector transformation by enhancing efficiency and sust...
Neutral
Business Wire
6 days ago
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer.
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Herve Hoppenot
Employees 2,524
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today